{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:09:55Z","timestamp":1772755795248,"version":"3.50.1"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2005,3,15]],"date-time":"2005-03-15T00:00:00Z","timestamp":1110844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2005,3,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Cytotoxic T lymphocytes (CTL) and highly active antiretroviral therapy (HAART) are known to exert strong evolutionary pressures on the virus population during human immunodeficiency virus (HIV) infection. However, it is not known whether CTL responses continue to substantially affect viral evolution during treatment. To study the effect of immunologic pressure on viral sequences during HAART, we identified 10 targeted HIV-specific CD8\n            <jats:sup>+<\/jats:sup>\n            -T-cell epitopes in five treatment-nai\u0308ve patients, sequenced each epitope in plasma-derived viruses, and then identified evidence of immunologic pressure at these epitopes by comparing the frequency of viral variants in plasma to the frequency of the CD8\n            <jats:sup>+<\/jats:sup>\n            -T-cell response for each variant identified. For one of the five patients, evidence of viral evolution was found during therapy. The sequence of the CTL-targeted epitope changed from an apparent escape variant prior to the initiation of therapy, to the sequence that is best recognized by the CTL response after the initiation of therapy, and then finally to a new escape variant during continued therapy. These data show that CTL-mediated pressure can continue to affect viral evolution after the initiation of HAART, even when treatment drives the viral load below detectable levels, and suggest that antiretroviral therapy may preferentially inhibit those virus variants that escape the CTL response.\n          <\/jats:p>","DOI":"10.1128\/jvi.79.6.3653-3663.2005","type":"journal-article","created":{"date-parts":[[2005,2,24]],"date-time":"2005-02-24T17:36:16Z","timestamp":1109266576000},"page":"3653-3663","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Immunologic Pressure within Class I-Restricted Cognate Human Immunodeficiency Virus Epitopes during Highly Active Antiretroviral Therapy"],"prefix":"10.1128","volume":"79","author":[{"given":"Joseph P.","family":"Casazza","sequence":"first","affiliation":[{"name":"Immunology Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Betts","sequence":"additional","affiliation":[{"name":"Immunology Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna J.","family":"Hill","sequence":"additional","affiliation":[{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Brenchley","sequence":"additional","affiliation":[{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Price","sequence":"additional","affiliation":[{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[{"name":"Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[{"name":"Immunology Laboratory"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.13.7069-7078.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.477"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.13.7330-7340.2003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5491.486"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.9.6103-6110.1994"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0297-205"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.22.10269-10273.2000"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1995.tb02422.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.14.6508-6516.2001"},{"key":"e_1_3_2_11_2","unstructured":"Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents 2001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/25374"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/15224"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402102"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112103052401"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0297-212"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.11.9404-9412.1999"},{"key":"e_1_3_2_18_2","first-page":"p","volume":"4","year":"2003","unstructured":"Hansen, T., and N. Myers. 2003. Peptide induction of surface expression of class I MHC, p. 18.11.1-18.11.8. In J. E. Colgan, A. M. Kruisbeer, D. H. Marguiles, and W. Strober (ed.), Current protocols in immunology, vol. 4. John Wiley & Sons, New York, N.Y.","journal-title":"Current protocols in immunology"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.171"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.2.196"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1621"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.6.991"},{"key":"e_1_3_2_23_2","first-page":"215","volume":"11","year":"2003","unstructured":"Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, R. T. D'Aquila, L. M. Demeter, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2003. Drug resistance mutations in HIV-1. Top. HIV Med.11:215-221.","journal-title":"Top. HIV Med."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.3.375"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0898-975"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0495-330"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.7.4650-4655.1994"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.8.5720-5730.1996"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0216028"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.21.10674-10684.2002"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112103052402"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.271"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199909100-00012"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069660"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.1.797-800.1999"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7371"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.20.10169-10176.2002"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.1.254"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/370463a0"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/387188a0"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5255.1582"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1890"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/71577"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.18.9481-9492.2002"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00375376"},{"key":"e_1_3_2_48_2","first-page":"95","volume":"4","year":"1996","unstructured":"Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1996. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News4:95-107.","journal-title":"Int. Antiviral News"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.283.5403.857"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119221"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-78-7-1511"},{"key":"e_1_3_2_52_2","unstructured":"Theoretical Biology and Biophysics Group. 1999. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group T-10 Los Alamos N.Mex."},{"key":"e_1_3_2_53_2","unstructured":"U.S. Public Health Service. 2001. 2001 USPHS\/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service Washington D.C."},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.4.1917"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.17.8690-8701.2002"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402101"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.79.6.3653-3663.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.79.6.3653-3663.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:04:56Z","timestamp":1646474696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.79.6.3653-3663.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,15]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,3,15]]}},"alternative-id":["10.1128\/JVI.79.6.3653-3663.2005"],"URL":"https:\/\/doi.org\/10.1128\/jvi.79.6.3653-3663.2005","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,15]]},"assertion":[{"value":"2004-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}